Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention
Authors:
- KwanKWKwan
Open Access
- 1 June 2011
- journal article
- research article
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. 7, 399-404
Abstract
Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention Joanne Kwan1, Wah Wah Htun2, Yili Huang3, Wilson Ko3, Tak W Kwan31Boston University, Boston, MA, USA; 2Lutheran Medical Center, Brooklyn, NY, USA; 3Beth Israel Medical Center, New York, NY, USABackground: The purpose of this study was to examine the effect of proton pump inhibitors (PPI) on the antiplatelet activity of clopidogrel in a consecutive series of Chinese patients after they had received coronary stents.Methods: A sample of 51 consecutive Chinese patients treated with coronary stents and taking PPI and clopidogrel for more than 30 days were enrolled in this study. Mean values for platelet residual units and percentage inhibition before PPI (+PPI) and 14 days after discontinuation of PPI (-PPI) were compared using the paired t-test.Results: There was no effect of concomitant use of esomeprazole and clopidogrel or omeprazole and clopidogrel on the inhibition assay, but platelet residual units and percentage inhibition showed statistically significant improvement after stopping lansoprazole in Chinese patients who were on chronic clopidogrel therapy. Clopidogrel resistance existed more frequently in the Chinese-American population examined, and was as high as 68% (+PPI) to 73% (-PPI).Conclusion: The clopidogrel resistance found is cause for concern, although its relationship with clinical events is currently unknown in this population. Further study with other thienopyridines or genetic variant analysis is suggested.Keywords: proton pump inhibitors, clopidogrel resistance, Chinese population, percutaneous coronary interventionKeywords
This publication has 35 references indexed in Scilit:
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- A population-based study of the drug interaction between proton pump inhibitors and clopidogrelCanadian Medical Association Journal, 2009
- Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary SyndromeJAMA, 2009
- Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patientsPharmacogenetics and Genomics, 2007
- Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.BMB Reports, 2007
- Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) studyThrombosis Research, 2007
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006
- An audit of upper gastrointestinal bleeding at Seremban Hospital.2003
- Stent Thrombosis in the Modern EraCirculation, 2001
- A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery StentsNew England Journal of Medicine, 1996